Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study

To estimate the intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping in locally advanced and trace mestastatic non-small cell lung cancer (NSCLC).

Why the study stopped: Lack of inclusion

Terminated

Looking for future studies?

Notify Me

Key information

Conditions

NSCLC

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gustave Roussy

Villejuif, Val de Marne, 94805, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Locally advanced NSCLC (stages IIB, IIIA or IIIB of the TNM classification 7th edition) or trace metastatic stage IV (</=5 mestastasis, </= 3 organ reached)
Exclusive therapeutic management by concomitant radio-chemotherapy administered in accordance with international recommendations (dual therapy with platinum salts)
Signed consent
Patients affiliated with the social security scheme or beneficiary of a similar scheme.

Exclusion criteria

Minor
Pregnant / lactating woman
Person deprived of liberty by judicial or administrative decision, adults who are the subject of a legal protection measure or unable to express their consent
Previous cancer in the 2 years prior to registration
Previousradiotherapy / thoracic surgery
Patients under experimental treatment or for whom the administration of an experimental treatment is planned
Claustrophobic patients
Severe Renal Insufficiency (Clearance MDRD Cockroft <30ml / min)
Uncontrolled diabetes, hyperglycemia> 1.8g / L
Patient with metallic implants not compatible with MRI or any immovable implanted electronic medical device (eg pacemaker, neurostimulator, cochlear implants, etc.)

Treatment and study plan

PET-MRI

Diagnostic Test

a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)
a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI).

Primary outcomes

Measurement of intra and inter-operator reproducibility of multiparametric regional PET-MRI mapping performed before and under treatment.

Time frame: Up to 24 months

Sponsors and collaborators

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Other

Registry information

Acronym: IMAHTEP

Important dates

Study start: 2017
Primary completion: 2019
Study completion: 2019
First posted: Jul 30, 2018
Registry last updated: Aug 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Terminated